Soligenix, Inc.
SNGXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Soligenix, Inc. (SNGX) is listed under Biotechnology. With a market capitalization of $8.3M, it sits in micro-cap territory. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions.
Market Cap
$8.3M
Beta
1.92
P/E (TTM)
—
P/E (Fwd)
-1.52
EPS (TTM)
$-0.72
EPS (Fwd)
$-0.25
ROE
-241.7%
ROA
-84.9%
Cash
$9.8M
Total Debt
$302,589
Free CF
-$6.3M
52W Change
-85.8%
Annual Financials
Cash vs Debt
Where SNGX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SNGX finished 47.95% below its 150-day moving average ($0.73) and 57.78% below its 200-day moving average ($0.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SNGX overbought or oversold?
At the September 3, 2026 close, SNGX's RSI(14) was 50.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Soligenix, Inc. holds $9.8M in cash against $303K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$6.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -241.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $250K (2022) to $0 (2025), a 100% decline worth watching.
Soligenix, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Soligenix, Inc. and its sector.